References
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med. 2001;344:783–92.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
- Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Mutations in the epidermal growth factor receptor and in kras are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–9.
- Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Kras mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
- Pietras K, Ostman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res. 2010;316:1324–31.
- Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7:513–20.
- Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle t oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954–61.
- Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007;5:323–8.
- Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirus middle t antigen. Microbiol Mol Biol Rev. 2009;73:542–63.
- Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, Mmtv mouse models and the diagnostic values of mmtv-like sequences in human breast cancer. Expert Rev Mol Diagn. 2009;9:423–40.
- Ponten F, Jirstrom K, Uhlen M. The human protein atlas—a tool for pathology. J Pathol. 2008;216:387–93.
- Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, The mammary pathology of genetically engineered mice: The consensus report and recommendations from the annapolis meeting. Oncogene. 2000;19:968–88.
- Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Paracrine signaling by platelet-derived growth factor-cc promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009;69:369–78.
- Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle. 2009;8:1461–2.
- Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5:1640–6.
- Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–63.
- Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, Vegfr1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–7.
- Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15:68–74.
- Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–27.